Conference Coverage

Conference Coverage

Compound targets mutated DLBCL, WM cells

SAN DIEGO—A Toll-like receptor (TLR) antagonist can target B-cell lymphoma cells harboring the MYD88 L265P mutation, preclinical research suggests...

Pages